 |
|
Tadalafil may effectively treat symptoms of BPH-LUTS in addition to erectile dysfunction
April 27, 2009Tadalafil may improve lower urinary tract symptoms in men with benign prostatic hyperplasia (BPH). Researchers from Nashville, Dallas, San Antonia and Indianapolis will present these findings during the 104th Annual Scientific Meeting of the American Urological Association (AUA).
In this study, researchers randomly separated 200 men, with an age equal to or older than 40 years and at least a six month diagnosis of BPH-LUTS with an International Prostate Symptom Score (IPPS) greater than or equal to 13, into two groups taking either 20 mg of tadalafil once daily or a placebo. After 12 weeks of treatment, the men taking tadalafil experienced improved detrusor pressure at urinary flow rate, peak flow rate (Qmax), bladder capacity, post-void residual volume and bladder voiding efficiency. Relative symptom improvement in the IPSS also was significantly better in the tadalafil group. At the end of the study, the proportion of obstructed patients in the placebo group increased, while the proportion in the tadalafil group decreased.
"Dr. Dmochowski, the study author, and colleagues have added further evidence to the growing body of research that suggests that in addition to their well known effect on erectile dysfunction, PDE-5 inhibitors may be able to help with management of bladder outlet symptoms as well. This is an exciting concept for men's health," said Anthony Y. Smith, MD, an AUA spokesman.
American Urological Association
American Urological Association
Benign Prostatic Hyperplasia Current Events and Benign Prostatic Hyperplasia News RSSNewly Discovered Gene Fusion May Lead to Improved Prostate Cancer Diagnosis
Researchers from NewYork-Presbyterian Hospital/Weill Cornell Medical Center have discovered a new gene fusion that is highly expressed in a subset of prostate cancers.
Drug for urination difficulties linked with complications after cataract surgery
Use of the medication tamsulosin to treat male urination difficulties within two weeks of cataract surgery is associated with an increased risk of serious postoperative ophthalmic adverse events such as retinal detachment or lost lens.
New ASCO/AUA guideline recommends men and their doctors discuss using 5-ARIs to reduce prostate cancer risk
A newly released joint guideline produced by the American Society of Clinical Oncology (ASCO) and the American Urological Association (AUA) recommends that healthy men who are screened regularly for prostate cancer and show no symptoms of the disease should talk to their doctors about using a 5-alpha reductase inhibitor (5-ARI) to prevent the disease.
Tadalafil shows promise for relief of lower urinary tract symptoms associated with BPH
Men with signs of benign prostatic hyperplasia (BPH) can be helped with a daily dose of erectile dysfunction drug tadalafil (Cialis®) to relieve associated lower urinary tract symptoms (LUTS), according to a new study published in the October 2008 issue of The Journal of Urology.
NIDDK Publishes a Strategic Plan for Research into Benign Prostate Disease
For the first time, a strategic plan for research into benign prostate disease, based on the latest scientific knowledge, has been published by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the National Institutes of Health (NIH).
Microwave treatments for enlarged prostate cause blood pressure surges
Many men who receive microwave therapy for enlarged prostates experience significant surges in blood pressure that could raise their risk of a heart attack or stroke, according to new research findings published recently in Mayo Clinic Proceedings.
Pros, cons of drug proven to prevent prostate cancer should be considered, researchers recommend
Findings by UT Southwestern Medical Center researchers encourage men to weigh both the potential benefits and side effects of the drug finasteride before taking it to prevent prostate cancer.
Study reveals high death toll after severe urinary complications in men over 45
As many as one in four men admitted to hospital with acute urinary retention will die within a year, finds a study published on bmj.com today.
Shrinkage of prostate led to overestimation of cancer risk in trial
Reanalysis of data from the first long-term randomized trial of a chemopreventive agent for prostate cancer shows that the excess prevalence of high-grade prostate cancer in the drug-treated group may be attributable to shrinkage of the prostate at the time of biopsy.
Severe form of 'enlarged prostate' disease discovered
Millions of middle-aged and older men experience the symptoms of an enlarged prostate multiple times during the day and night. What they may not know is that the disease known as BPH (benign prostatic hyperplasia), marked by urgency and frequent urination, is not one but at least a pair of disorders, and that one of the pair-tied to a newly identified gene-has far more serious implications.
More Benign Prostatic Hyperplasia Current Events and Benign Prostatic Hyperplasia News Articles
 |
Textbook of Benign Prostatic Hyperplasia by Roger S. Kirby (Editor), John D. McConnell (Editor), John M. Fitzpatrick (Editor), Claus G. Roehrborn (Editor), Peter Boyle (Editor) Completely revised and updated, Textbook of Benign Prostatic Hyperplasia, Second Edition provides a state-of-the-art overview of the entire field. The first edition of this breakthrough book was very well received by urologists around the world and became the standard reference work on the subject of Benign Prostatic Hyperplasia (BPH). With the constant changes and improvements being made in therapeutics and treatment in general, any book on this important subject needs to be updated frequently. The first edition's original sections have been expanded and, once again, a team of expert editors and contributors ensure that the material presented reflects the latest available information.The editorial panel examines all aspects of the disorder, from pathophysiology to the latest... |
 |
Prostate Miracle Is a Natural, Highly Effective Treatment for Benign Prostatic Hyperplasia and Prostatitis - 1 Bottle by Your Health Supply Prostate Miracle is a Natural, Highly Effective Treatment for BPH Prostate Miracle is formulated using USA produced beta-sitosterol (extracted from soy). Each 100% vegetable capsule contains 300 mg of beta-sitosterol, making it 3,000 times more potent than saw palmetto. You would have to eat 2 lbs. of saw palmetto berries to get the same amount of beta-sitosterol that Prostate Miracle provides in ONE capsule. NO SIDE EFFECTS -Prostate Miracle combines the 4 most important natural nutrients for promoting prostate health (in the correct amounts to be effective) 300 mg of Beta-Sitosterol with 7.5 mg of Zinc Citrate, 100 mcg of Selenium and 1000 iu's of Vitamin D3. -Prostate Miracle is effective in 95% of patients, significantly decreasing the prostate size while dramatically reducing BPH... |
|
Benign Prostatic Hyperplasia | |
 |
Ayurstate for Prostate Care & Benign Prostatic Hyperplasia (BPH) - 60 Capsules (1 Month Supply) by India Herbs Ayurstate contains the 8 most potent prostate rejuvenating herbal concentrates available in Ayurvedic Science and backed by clinical studies. When formulated in the correct amounts and blended by our proprietary process, 50 natural phytonutrients exert 250 synergistic activities on your body to decrease the size of your prostate and reduce urethra inflammation by inhibiting the production of damaging metabolites and enzymes. It will also improve your urine flow, semen production, and ejaculation control in a safe and natural manner with no side effects. Ayurstate nourishes and stimulates the exocrine glands to relieve effects of prostate-related problems by normalizing the size of your prostate and keeping it from getting larger as a result of exposure to excess estrogen. This is... |
|
Urologic Clinics of North America: August 1990 (Benign Prostatic Hyperplasia, Volume 17) by Patrick Walsh Herbert Lepor (Author) | |
 |
Benign Prostatic Hyperplasia AHCPR Clinical Practice Guideline/Tumor Suppressor Genes in Human Cancer (NCME Video 658) Also With: Network For Continuing Medical Education (Primary Contributor), John Wasson (Primary Contributor), Daniel A Haber (Primary Contributor) In February, 1994, the Agency for Health Care Policy and Research (AHCPR) released a clinical practice guideline dealing with the diagnosis and treatment of benign prostatic hyperplasia. This telecourse presents highlights of that guideline. In the 1980's, the study of positive oncogenes was a major focus in the quest to understand the molecular origins of cancer. Today, tumor suppressor genes are sharing the spotlight and may exemplify an untapped resource for anticancer therapy. Dr. Haber demonstrates how recessive oncogenes, which normally control cell growth, allows cells to progress to malignancy when lost or inactivated. |
|
Management of Benign Prostatic Hyperplasia for Primary Care--VHS Clinical Rounds Satellite Broadcast-May 23, 1996. Department of Veterans Affairs Birmingham Education Center. Time 1:33:37 | |
|
Benign Prostatic Hyperplasia (Fast Facts) by Roger S. Kirby (Author) The fifth edition of this popular book by two world-renowned experts contains concise, up-to-date practical information, including new management guidelines and the results of recent clinical studies. Treatment strategies are discussed with an emphasis on patient involvement and preference. Fast Facts - Benign prostatic hyperplasia will be an invaluable resource for any healthcare professional treating this bothersome disease. | |
 |
Benign Prostatic Hyperplasia (Fast Facts) by Roger S. Kirby (Author), John D. McConnell (Author) St. George's Hospital, London, UK. Pocket-sized quick reference of practical information on benign prostatic hyperplasia. Contains color illustrations, tables, and charts. Previous edition: c1997. Softcover. |
 |
Contemporary Diagnosis and Management of Benign Prostatic Hyperplasia by Claus G. Roehrborn (Author), MD (Author) Benign prostatic hyperplasia (BPH) is present in about half of the male population over the age of 50. This first-edition handbook written by Claus G. Roehborn, MD, the foremost BPH specialist in the world, discusses the latest medical therapies and surgical treatments to slow the development of BPH, which will become a major diagnostic concern for primary care physicians as the percentage of eldery men in the United States continues to grow. |
| © 2009 BrightSurf.com |